FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1301-1302 October 21, 1999 Number 17 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Silverberg, S. J. PubMed Citation

Hypercalcemia, and subsequently primary hyperparathyroidism, is discovered in two ways. Most commonly, hypercalcemia is discovered when serum calcium is measured as a screening test or in patients who have fatigue, weakness, or other symptoms of physical or neuropsychological disability. Much less often, it is discovered when serum calcium is measured in patients with nephrolithiasis or osteopenia, the two main complications of hyperparathyroidism. Unless the cause of the hypercalcemia is obvious — for example, the patient has cancer or is taking large doses of vitamin D — the next step is measurement of serum parathyroid hormone. A high or even inappropriately . . . [Full Text of this Article]

References

Related Letters:

Treatment of Primary Hyperparathyroidism
Glendenning P., Gutteridge D. H., Retallack R. W., Utiger R. D.
Extract | Full Text  
N Engl J Med 2000; 342:976-977, Mar 30, 2000. Correspondence

This article has been cited by other articles:

• El-Hajj Fuleihan, G. (2008). Hyperparathyroidism: Time to Reconsider Current Clinical Decision Paradigms?. J. Clin. Endocrinol. Metab. 93: 3302-3304 [Full Text]  
• Cappelli, C., Pelizzari, G., Pirola, I., Gandossi, E., De Martino, E., Delbarba, A., Agosti, B., Agabiti Rosei, E., Castellano, M. (2008). Modified percutaneous ethanol injection of parathyroid adenoma in primary hyperparathyroidism. QJM 101: 657-662 [Abstract] [Full Text]  
• Reppe, S., Stilgren, L., Abrahamsen, B., Olstad, O. K., Cero, F., Brixen, K., Nissen-Meyer, L. S., Gautvik, K. M. (2007). Abnormal muscle and hematopoietic gene expression may be important for clinical morbidity in primary hyperparathyroidism. Am. J. Physiol. Endocrinol. Metab. 292: E1465-E1473 [Abstract] [Full Text]  
• Bolland, M. J., Grey, A. B., Gamble, G. D., Reid, I. R. (2005). Association between Primary Hyperparathyroidism and Increased Body Weight: A Meta-Analysis. J. Clin. Endocrinol. Metab. 90: 1525-1530 [Abstract] [Full Text]  
• Khan, A. A., Bilezikian, J. P., Kung, A. W. C., Ahmed, M. M., Dubois, S. J., Ho, A. Y. Y., Schussheim, D., Rubin, M. R., Shaikh, A. M., Silverberg, S. J., Standish, T. I., Syed, Z., Syed, Z. A. (2004). Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial. J. Clin. Endocrinol. Metab. 89: 3319-3325 [Abstract] [Full Text]  
• Clark, O. H. (2003). How Should Patients with Primary Hyperparathyroidism Be Treated?. J. Clin. Endocrinol. Metab. 88: 3011-3014 [Full Text]  
• Sackett, W. R., Barraclough, B., Reeve, T. S., Delbridge, L. W. (2002). Worldwide Trends in the Surgical Treatment of Primary Hyperparathyroidism in the Era of Minimally Invasive Parathyroidectomy. Arch Surg 137: 1055-1059 [Abstract] [Full Text]  
• Schmaldienst, S., Dittrich, E., Pietschmann, P., Niederle, B., Becherer, A., Watschinger, B. (2001). A patient with evidence of two underlying diseases causing hypercalcaemia. Nephrol Dial Transplant 16: 2423-2425 [Full Text]  
• Prager, G., Czerny, C., Kurtaran, A., Passler, C., Scheuba, C., Bieglmayer, C., Niederle, B. (2001). Minimally Invasive Open Parathyroidectomy in an Endemic Goiter Area: A Prospective Study. Arch Surg 136: 810-816 [Abstract] [Full Text]  
• Glendenning, P., Gutteridge, D. H., Retallack, R. W., Utiger, R. D. (2000). Treatment of Primary Hyperparathyroidism. NEJM 342: 976-977 [Full Text]